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Abstract
Hemostasis in cardiac surgery is still a severe problem for surgeons. Blood and 
its products are the most valuable at the same time dangerous arms of surgeons. 
Industries produced many biological or non-biological products, which increase the 
cost of operations, are available for this issue. Decision making and producing solu-
tions must be the most important properties of a cardiac surgeon. In any condition 
and resources, true strategy and patience will bring the success. Antiaggregants and 
anticoagulants are widely used agents, and in emergency or early cases, surgeons 
have to operate these patients. Both groups of drugs are growing, and in an emer-
gency position, it is hard to know which drugs the patient using or given and what 
kind of medical status he/she has. For example non vitamin-K oral anticoagulants 
newer drugs and not known so much except cardiologists and cardiovascular 
surgeons. Simple solutions may have better results. Of course, in some conditions, 
urgent consultation can solve the problem. Cardiac surgeons have to figure out the 
problem by using their experience and surgical materials. Working as a team is a big 
advantage, more than one surgeon, experienced operation nurses and closer follow 
up in intensive care unit.
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1. Introduction
Since 1956 Gibbon’s first ASD closure using a heart-lung machine, cardiac 
surgery has made great strides. However, bleeding is still the fearful dream of 
surgeons. According to the World Bank, in upper-middle-income countries as in 
Turkey, certain restrictions are compulsorily brought to health-care costs. In this 
case, about 2000 US dollars is paid for open heart surgery in the social security 
system in Turkey. However, in today’s conditions, the costs have exceeded the fee 
paid by the social security institution, and in this case, public hospitals continue to 
provide health-care services despite the loss. On the other hand, the society is aging, 
and compulsorily, the riskier patients are being operated, but the prolonged length 
of intensive care and the hospital stay of these patients increase the costs. In this 
case, the solution is to provide services with serious sacrifices on the basis of health 
care providers and institutions, especially surgeons. The main principle here should 
be to evaluate the patient well before the operation and to gain the patient during 
the operation and to pass through the intensive care period without any problem. 
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This can only be the result of achieving good cardiac functions and hemostasis with 
a successful operation.
Cardiac surgery is associated with an invasive procedure, serious anticoagula-
tion requirement and perioperative blood loss due to cardiopulmonary bypass and 
accordingly high-probability allogenic blood transfusion. Risk factors:
i. Hemodilution (prime of cardiopulmonary bypass, cardioplegia, and periop-
erative fluids)
ii. Coagulation and fibrinolysis activation
iii. A consumptive coagulopathy
iv. Anticoagulation with unfractionated heparin
v. Other physiological disorders such as hypothermia, hypocalcemia,  
academia [1].
In cardiac surgery, patient blood management (PBM) contributes to the main-
tenance of perioperative hemostasis, which reduces the requirement for blood 
transfusion [2]. Both the use of high amounts of blood products and the require-
ment for reoperation are linked to undesirable clinical outcomes [3, 4]. The use 
of one or two units of packed red blood cells (PRBCs) in coronary artery bypass 
grafting (CABG) patients is associated with increased cost as well as dramatic 
mortality and morbidity [5]. However, it is unclear whether these complications 
are independent predictors of outcome or a sign of the complexity and complica-
tions of surgery [2]. In any case, re-exploration due to bleeding and tamponade is a 
strong predictor of early postoperative mortality and morbidity. It should be kept 
in mind that not performing re-exploration when it is required brings about more 
serious consequences. There is, however, no general consensus on when exploration 
for postoperative bleeding is indicated, and surgical practice varies considerably in 
this regard [6]. There may be limited resources to achieve hemostasis, as well as to 
detect cardiac tamponade or when the patient will be re-explored for bleeding. The 
cardiac surgeon should be skeptical about this and use all arguments in his or her 
hand. Hemodynamic deterioration, decrease in urine output, decreasing Hb levels 
while increasing base gap and lactate levels in blood gas analysis, deterioration in 
general condition of the patient and chest pain, and most importantly enlarged 
mediastinum on chest radiogram, hematoma accumulation in lung fields are the 
most important manifestations of cardiac tamponade and bleeding. The patient 
should be re-explored without hesitation. It should not be compromised on surgical 
site cleaning and antisepsis in postoperative cardiac tamponade patients, who are 
usually opened urgently with impaired hemodynamics. After the urgent removal of 
hematomas, anastomoses and cardiotomies should be checked first. After bleed-
ing control, the patency of drainage tubes should be checked and they should be 
replaced, if necessary.
Numerous factors such as advanced age, preoperative dual antiplatelet therapy 
(DAPT), platelet dysfunction, preoperative anemia, small body surface area, female 
gender, non-elective surgery, non-isolated surgery, non-CABG surgery, and redo 
surgery are associated with increased bleeding [7–9].
A group of hemostatic agents including topical hemostats, sealants and adhe-
sives are available to stop these bleedings. Despite these, hemostasis cannot be 
achieved due to the inappropriate use of hemostatic agents in 40% of surgical 
patients, as in the surgery of traumatic injuries [10].
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2. Preoperative management
Failure to adequately optimize the patient prior to surgery increases the risk 
of bleeding and anemia during the operation [2]. The use of routine preoperative 
screenings has been highly discussed in terms of its ability to identify high-risk 
patients for postoperative bleeding and transfusion requirements. Preoperatively 
determined prothrombin time or the activated partial thromboplastin time (aPTT) 
could not be associated with perioperative blood loss or transfusion requirements 
[11–13]. The most commonly identified risk factor for postoperative bleeding is a 
low fibrinogen level [11, 12, 14–16]. However, despite its association with bleeding, 
the positive predictive value of a low-fibrinogen level remains poor (positive predic-
tive value <20%) [15]. A low platelet count (<10,010–9/L) has been associated with 
increased risk of transfusion, and patients with the highest postoperative blood loss 
volumes show the lowest platelet counts [12]. It has been shown that patients with 
the highest postoperative blood loss volumes show the lowest thrombin generation 
rates, but this test is mainly used for research purposes and is not routinely used in 
everyday practice [12, 17].
In preoperative Hb evaluations of 1388 female and 3265 male patients undergo-
ing elective cardiac surgery, it was found that borderline anemia (defined as the 
hemoglobin concentration of 120–129 g L−1) was more common in the female group 
and about one-third of the patients were in this range. These women had increased 
morbidity, reflected by increased red cell transfusion and prolonged hospital stay 
compared with non-anemic women (Hb >130 g L−1). It was also found that these 
women received more erythrocyte transfusion than male patients [18].
2.1 Preoperative drugs and their effects on postoperative bleeding
2.1.1 Acetylsalicylic acid
Acetylsalicylic acid (ASA) is one of the cornerstones for the treatment of acute 
and chronic cardiovascular disease. Primary and secondary prevention with ASA 
has been shown to reduce mortality, myocardial infarction (MI) and stroke but to 
increase the risk of bleeding complications [19]. All patients requiring emergency 
or elective CABG are treated with ASA. A meta-analysis showed that ASA reduced 
the risk of perioperative MI [odds ratio (OR) 0.56, 95% confidence interval (CI) 
0.33–0.96] but not the risk of death (OR 1.16, 95% CI 0.42–3.22). Twelve-hour 
blood loss, PRBC transfusions and surgical re-exploration increased with ASA 
[20]. A large RCT compared the administration of ASA (100 mg) on the day of 
surgery versus placebo in patients having CABG [49]. The study showed no effect of 
treatment with ASA on 24-h bleeding (mean blood loss: 780 vs. 740 mL; P = 0.30) 
or on the incidence of death or thrombotic complications (19.3 vs. 20.4%; P = 0.55). 
Because patients were only eligible for inclusion if they were not using ASA or 
stopped ASA >4 days before surgery, these findings are difficult to generalize to 
other settings [21]. In another randomized clinical study, the use of preoperative 
300 mg ASA was associated with post-surgical drainage of over 1000 mL [22].
Given all these results, the continuation of ASA treatment in patients undergo-
ing CABG may be reason of increasing postoperative blood loss while reducing 
ischemic event [2]. In patients with high probability of re-exploration such as those 
who refuse the blood transfusion, who will undergo non-CABG surgery, complex 
cases, redo operations, and those who have severe renal failure, hematologic and 
inherited platelet function disorders, ASA should be discontinued 5 days before 
surgery. Prevention of thrombotic events outweighs the risk of bleeding in other 
patients. Current information suggests that ASA-inhibited platelet aggregation can 
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be reversed by platelet transfusion, which supports the continuation of ASA treat-
ment until operation [23, 24]. Mortality rates significantly decrease in patients who 
are initiated on ASA in the first 48 h after CABG compared to patients who are not 
initiated on ASA (1.3 vs. 4% P < 0.001) [25].
2.1.2 Dual antiplatelet therapy (DAPT)
The administration of DAPT, a P2Y12—receptor antagonist (clopidogrel, 
ticagrelor and prasugrel), in combination with ASA significantly reduces the risk 
of thrombotic complications in acute coronary syndromes compared to ASA alone 
[26]. Compared to clopidogrel, the risk of thrombotic complications is significantly 
reduced by ticagrelor and prasugrel, the second generation P2Y12 antagonists, while 
the risk of both spontaneous and surgical bleeding increases significantly [27]. 
Recently, cangrelor, a new reversible intravenous P2Y12 inhibitor with an ultrashort 
half-life to offset the effect after discontinuation, was introduced [28].
2.1.3 Glycoprotein IIb/IIIa inhibitors
Today, glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors (eptifibatide, tirofiban and 
abciximab) are almost exclusively used in conjunction with percutaneous coronary 
interventions, but may also be used for bridging high-risk patients on oral P2Y12 
inhibitors to surgery [29, 30]. The discontinuation times of these drugs before sur-
gery are based on pharmacokinetic assumptions. The recovery of platelet functions 
is obtained within 24–48 h for abciximab and 4–8 h for eptifibatide and tirofiban 
[31]. In a small retrospective study, tirofiban-treated patients having CABG showed 
more bleeding than patients who were not treated with tirofiban, but there was no 
difference between different discontinuation times [32]. Discontinuation of GPIIb/
IIIa inhibitor at least 4 h before surgery should be considered to minimize the risk 
of postoperative bleeding.
2.1.4 Low-molecular-weight heparin
As enoxaparin and fondaparinux, LMWH mainly functions by inhibiting factor 
Xa and reaches plasma peak levels 3–4 h after the administration. In patients with 
normal renal function, their half-life is 5 h. Their anticoagulant effects can be 
monitored by measuring plasma anti-FXa activities. LMWH-induced bleeding may 
be treated with protamine, but this therapy does not completely reverse the antico-
agulant effect of LMWH [2].
2.1.5 Vitamin K antagonists
Vitamin K antagonists (VKAs) are commonly used to prevent and treat throm-
boembolism in cases of atrial fibrillation, venous thromboembolic disease and 
mechanical heart valve. They are monitored by the international normalized ratio 
(INR) and prothrombin time. They should be stopped 3–5 days before surgery to 
obtain an INR <1.5. For emergency surgeries, their effects are completely reversed 
by prothrombin complex concentrate. Bridging non-cardiac surgery patients who 
are taking VKA with a full therapeutic dose of LMWH after surgery are associated 
with increased risk of bleeding but not with a significant reduction in thrombotic 
events [33]. Elective cardiac surgery is not recommended unless the INR value falls 
below 1.5. In cases where surgery cannot be postponed, coagulation factors should 
be used to antagonize the effects [2].
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2.1.6 Direct oral anticoagulant
Direct oral anticoagulants (DOACs) is a group of drugs consisting of dabiga-
tran, a direct thrombin inhibitor, and rivaroxaban, apixaban and edoxaban, oral 
FXa inhibitors, and novel formulations under development. They are increas-
ingly used as an alternative anticoagulation strategy for VKAs [2]. Since emer-
gency surgery in patients under dabigatran treatment has been associated with 
severe or even fatal bleeding, it is recommended that these drugs be discontinued 
48 h before cardiac surgery [34–36]. The half-life of DOACs may be prolonged 
in the case of impaired renal function. For emergency reversal of dabigatran, 
the newly released antidote (idarucizumab) can be used in the pre- and post-
operative settings. Treatment of postoperative FXa-related bleeding includes 
PCC, activated PCC (FEIBAV R, Shire US Inc., Lexington, MA, USA) and 
recombinant activated factor VII (rFVIIa), since no specific antidote is approved 
at the moment [2].
According to the EACTS/EACTA recommendations, ASA should be continued 
in the preoperative period in patients scheduled for CABG (Class IIa, Level C). 
ASA should be discontinued 5 days in advance (Class IIa, Level C) in patients with 
a high risk of bleeding, refusing the blood transfusion, or undergoing cardiac 
surgery other than CABG. If there is no severe bleeding in the first 24 h postop-
eratively, ASA should be initiated in isolated CABG patients (Class I, level B). If 
CABG is not urgent, ticagrelor should be discontinued 3 days, clopidogrel 7 days 
and prasugrel should be discontinued 5 days before surgery in patients taking 
DAPT (Class IIa, Level B). GPIIb/IIIa inhibitors should be discontinued 4 h before 
surgery (Class IIa, Level B). GP IIb/IIIa inhibitors should be discontinued 4 h 
before surgery (Class I, Level C). In order to reduce the risk of bleeding, oral anti-
coagulants should be discontinued only in patients with a high risk of thrombosis 
and it should be continued with UFH/LMWH (Class I, Level B). LMWHs should 
be discontinued 12 h before and fondaparinux before should be discontinued 24 h 
before (Class I, Level B). In the use of VKAs, surgery should be performed after the 
INR value reduces below 1.5 (Class IIa, Level C). DOACs should be discontinued 
48 h before cardiac surgery (Class IIa, Level C).
3. Clinical effects of surgical bleeding
Bleeding is the most important complication of surgery, which increases 
mortality and morbidity rates [37–39]. Uncontrolled bleeding results in adverse 
clinical outcomes including anemia, hemodynamic instability, hypothermia, 
hypovolemia, reduced oxygen delivery to tissues, impaired visualization of the 
surgical site, and prolonged operative time. Surgical bleeding requires expensive 
blood transfusion and re-operation, in which a large amount of clinical and per-
sonnel resources is used [39]. Major bleeding is also associated with an increased 
risk of postoperative mortality reaching 20% in vascular surgery and 30–40% in 
trauma surgery [39].
Blood transfusion itself involves many risks. Transfusion-related acute lung injury, 
which occurs one in every 1000–5000 plasma and erythrocyte transfusions, is the 
leading cause of mortality and morbidity [40]. Bacterial contamination, which occurs 
one in every 2000–3000 platelet transfusions, is another complication of transfusion 
[40]. The authors have reported that the length of hospital stay is longer in patients 
with bleeding-related complications or more blood transfusion requirements than 
those without bleeding complications (10.4 vs. 4.4 days, respectively) [41].
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3.1 Economic effects of surgical bleeding
Uncontrolled bleeding and transfusion requirement are associated with bleed-
ing complications, resulting in a considerable amount of cost [42]. Stokes et al. also 
compared the total hospitalization costs for patients with bleeding-related compli-
cations or blood transfusions with those for patients without any complication and, 
again, noted a significant increase in costs among those with complications [41]. 
There are, of course, the costs of bleeding and blood and blood transfusion for all 
countries. In the country where I work, these costs are not as high as in the US.
It should be kept in mind that although blood transfusion is an indispensable 
treatment, whether clinical or economic, it is the most dangerous drug we have ever 
used [43].
3.2 Clinical responses to surgical bleeding
The surgical nurse plays an important role in optimizing hemostatic applications 
throughout the operation. To meet the requirements for hemostasis by questioning 
the surgeon before and during surgery. To know the material available to meet the 
requirements for surgical intervention. To adjust the time required for the prepara-
tion of the necessary material during the operation and be in constant communica-
tion with the surgeon [42]. Working with a nurse experienced in cardiovascular 
surgery is always a significant advantage for the surgeon. In general, I trained my 
surgical nurses myself in private hospitals where I worked in my surgical life. Private 
hospitals try to minimize the number of staff in order to limit input cost due to their 
commercial concerns. They also prefer less educated staff. At this point, the respon-
sibility of the surgeon increases, s/he has to perform a successful operation while 
continuing the training activities of the nurse. In this respect, cardiovascular surgery 
centers in many private, public and universities in my country train their own surgi-
cal nurses. Personally, I have also trained many nurses and even made them gain the 
qualifications to perform proximal anastomosis and connect prolene sutures. After 
a while, the surgical nurse could follow the operation, know what to be asked in 
advance and quickly prepare the required instrument and material. In my opinion, 
the most serious disadvantage of this is that you are on your own in decision making 
since there is no experienced assistant surgeon assisting you (Figures 1 and 2).
Selection of the most appropriate method for achieving hemostasis is based on 
correctly defining the nature and severity of the patient’s bleeding. If the patient 
presents with or develops uncontrolled bleeding in the operating room, first and 
Figure 1. 
Saphenous vein graft anastomosis to coronary artery. Small bites from epicardial tissue with appropriate size 
prolene suture.
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to the extent permitted by time, a group of coagulation laboratory values (pro-
thrombin time/international normalized ratio, activated partial thromboplastin 
time, complete blood count with differential and platelets, activated clotting time, 
fibrinogen, d-dimer and thromboelastography) should be examined [42]. In cases 
of unexpected or complex coagulopathy, it is necessary to get professional help 
from a subspecialist such as a hematologist and blood bank specialist. (While such 
aids actually work in intensive care follow-ups, it seems difficult for the specialist to 
comprehend the situation in the operation room and offer solutions in the complex-
ity of the surgery. Therefore, the responsible surgeon must be able to master these 
issues and produce urgent solutions.) (Figure 3).
4. Mechanical solutions
Mechanical approaches usually provide hemostasis without the need for any 
hemostatic product. The most basic practice is to apply compression with finger or 
fingers to the bleeding site. Especially in bleedings of the tissues with high pressure 
Figure 2. 
Saphenous vein graft anastomosis to coronary artery. Small clips for the small branches of the saphenous graft.
Figure 3. 
Here is a left mammarian artery graft anastomosis to left anterior descending artery. A small retractor used for 
easy visualization of the arteriotomy. Again usage of small clips. When you are performing the repair sutures to 
bleeding side of the anastomoses, you have to be careful and you do not need to pass the whole layers of coronary 
artery.
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such as the ascending aorta, compression should absolutely be applied with finger 
to save time for strategies to create solutions. In fact, it is the most basic approach to 
be performed in the case of unexpected bleedings during a routine operation. While 
the surgeon is using the fingers of his/her non-dominant hand to restrict bleeding, s/
he should give the surgical nurse order for repair. Here, a few simple maneuvers can 
be life-saving. The venous return should be reduced for lowering the pressure in the 
ascending aorta. Tilting the patient’s head up by operating table is simple and effec-
tive. If you fail for lowering the arterial pressure, transient inferior caval clamping 
before neutralization of heparin may be very helpful, especially when pulling out the 
aortic cannula. Another technique in old textbooks is total inflow occlusion. In this 
technique, it has been described that repairs are carried out in a few minutes with 
cross-clamps placed on both cavas. However, when removing the caval cross clamp, 
it should be absolutely ensured that the clamp is fully opened. Moreover, a simple 
approach in aortic cannulation is using teflon pledgets for outer purse-string suture.
The most basic hemostasis approach is to create a mechanical barrier. The use of 
a needle and suture in an appropriate size and supporting it with teflon pledgets is 
the most effective, simple and accurate approach. The suture material to be selected 
is usually prolene. In order to reduce tissue injury, the needle should be as small as 
possible along with fine needles, but of sufficient thickness to withstand the tension 
in the tissue and appropriate thickness to be securely attached. (The most important 
issue to be considered here is that the other hand knot should be tied tightly enough 
to stop bleeding and ensure tissue integrity not to allow non-dominant hand suture 
to loosen when making a suture. Excessively tight and hard knots may cause more 
severe tissue injuries and bleedings.) For sutures that will both stop bleeding and 
provide anastomosis, it is necessary to use stronger fibrous tissues of the patient 
such as the adventitia and epicardial layer (Figure 4).
Sponges are the most commonly used inexpensive materials to stop bleeding in 
the operation field. They are very effective with mechanical compression, especially 
in oozing-type bleedings. Sponges should be intensely applied to the mediastinum 
after the clamps are removed and it should be waited until the end of protamine 
neutralization. As a result of reapplication of a clean sponge, especially after ending 
the heparin effect, locally contaminated sponges may give information about the 
site of bleeding other than providing hemostasis (Figure 5).
Hemoclips are an effective and fast method especially for harvesting arterial grafts 
and ligating small vessels. However, it is necessary to pay particular attention to the 
Figure 4. 
Two anastomoses to LAD. There is no bleeding from anastomotic sides.
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selection of hemoclips. Especially, large hemoclips may damage a small vessel and 
increase bleeding as a result of tissue injury. It is important to remember that these 
hemoclips may drop when applying sponge to the operation site or performing bleed-
ing control. Therefore, ligation or suturing may be more effective in appropriate cases.
Other mechanical solutions include electrosurgery, laser, radio-frequency 
energy, argon beam coagulation, ultrasonic scalpel or ultrasonic surgical aspirator 
use. When using electrocautery, it is beneficial to use it at the lowest energy and 
appropriate program that can do our work. It should be kept in mind that especially 
high energy will increase tissue injury.
5. Pharmacological drugs
Pharmacological strategies for blood preservation are also an important tool 
in the arsenal of the surgical team since these agents alleviate the activation of the 
hemostatic system without the clinical and economic consequences associated 
with transfusion [44]. Pharmacological agents may be of some benefit in diffuse 
surgical bleedings or in those with a hemostatic defect. These agents may be used 
in combination with surgical hemostatic agents. These agents are recombinant 
factor VIIa, desamino-d-arginine vasopressin, and antifibrinolytics (e.g., epsilon 
aminocaproic acid (EACA), tranexamic acid (TXA)) [44, 45]. The recombinant 
factor VIIa activates platelets to increase thrombin production. It is used in trauma 
and surgical refractory bleeding. It acts quickly and is quite expensive. Although it 
is not a preferred product in our country, we prefer fresh frozen plasma (FFP) in 
such cases. Desmopressin acetate (vasopressin) factor VIII is a selective V2 agonist 
that causes the release of von Willebrand factor and tissue plasminogen activator. 
It is used in platelet dysfunction. It acts in a short time, tachyphylaxis and repeated 
doses increase the risk of bleeding. The parenteral form is not available in Turkey, 
the nasal spray form is not very effective.
Antifibrinolytic therapy reduces bleeding, the use of blood and blood products 
and reoperations due to bleeding [2]. This group includes tranexamic acid (TXA), 
aprotinin and EACA. The sale of aprotinin has stopped in some countries, especially 
because it increases mortality rates.
The Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) 
randomized controlled trial compared TXA with placebo in patients undergoing 
Figure 5. 
No bleeding from proximal anastomotic sides of sapheneous vein grafts. Also adventitial tissue bites performed. 
Sponges under the retractor compress the cavernous tissue of sternum.
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CABG surgery and demonstrated a reduction in the risk for reoperation due to 
major hemorrhage (RR 0.36, 95% CI 0.21–0.62; P < 0.001) and in the need for the 
transfusion of any blood products (37.9 vs. 54.7%; P < 0.001.(13 C)). In a systemic 
review and cumulative meta-analysis comparing those having cardiac surgery with 
the control group, TXA was shown to reduce the requirement for blood transfusion 
[47]. The most significant reported side effect of TXA was a convulsive seizure 
[48]. The findings from the ATACAS trial showed that low-dose (50 mg/kg) versus 
high-dose (100 mg/kg) TXA was not safer in terms of seizures (0.7 vs. 0.6%, 
respectively), but the higher dose significantly reduced blood loss (P = 0.026) and 
PRBC transfusion (P = 0.017) [46].
Tranexamic acid is also an antifibrinolytic agent that we use frequently. It 
inhibits plasmin and plasminogen proteases and reduces surgical bleeding. It may 
cause thrombosis and hypotension.
6. Transfusion
These blood products include FFP, platelets, prothrombin complex concentrate, 
cryoprecipitate, and whole blood. Thrombocytes in plasma are indicated when 
platelet levels are less than 50 × 109/L. It contains cryoprecipitate factor VIII, von 
Willebrand factor, fibrinogen and fibronectin, and is indicated when the patient’s 
fibrinogen is less than 100 mg/mL or when the patient has von Willebrand fac-
tor deficiency [49]. FFP contains coagulation factors and fibrinogen in variable 
amounts, while prothrombin complex concentrate contains factors II, VII, IX, and 
X and prothrombin, as well as proteins in variable amounts. Both FFP and pro-
thrombin complex concentrate are indicated when a surgical patient who is bleed-
ing has an international normalized ratio greater than 1.5 [49].
6.1 Fresh frozen plasma
FFP is obtained from the plasma of volunteer blood donors containing coagulation 
factors and other proteins. An increasing number of countries use pooled plasma. 
Pooled plasma contains plasma from multiple donors and is inactivated for viruses 
with a lower risk of transfusion-induced lung injury [2]. The largest body of evidence 
is gathered on the prophylactic administration of FFP to patients without a diagnosed 
coagulopathy and is summarized in a Cochrane review and three other systematic 
reviews [50–53]. In patients undergoing cardiac surgery, there was no difference in 
blood loss and allogeneic blood transfusion requirement when patients intraopera-
tively receiving FFP were compared with the control group. The RCTs included were 
limited by small sample sizes and divergent doses of FFP [51–53]. It has also been 
shown that FFP is not effective in 24-h blood loss in patients with diagnosed coagu-
lopathy or in the reversal of oral anticoagulation when it is used at a therapeutic dose 
[51, 53]. In summary, FFP might be used to reverse the action of oral anticoagulation 
or in the case of persistent perioperative bleeding, but there is no evidence that pro-
phylactic or therapeutic FFP transfusions reduce blood loss after cardiac surgery [2].
7. Topical hemostats
Topical hemostatic agents consisting of mechanical, active, flowable, and fibrin 
sealants provide hemostasis by forming blood clots [54–56]. Agents in this class 
vary greatly with respect to safety, efficacy, usability, and cost. An appropriate 
agent should be selected for each clinical situation.
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7.1 Mechanical hemostats
It consists of combining hemostatic agent and sponge, foam or pad absorbable 
material. They create a surface against blood flow where blood clots can form [56]. 
Common mechanical hemostatic agents include porcine gelatin products (e.g., 
Gelfoam®, Gelfoam Plus®, Surgifoam®), cellulose products (e.g., Surgicel®, 
Surgicel Fibrillar™, Surgicel Nu-Knit®), bovine collagen products (e.g., Avitene™ 
sheets, Avitene Ultrafoam™ collagen sponges), and polysaccharide spheres (e.g., 
Arísta®, Hemostase MPH®, Vitasure™) [54–56]. They are effective in minimal 
bleedings and when the coagulation cascade is normal. They are easy to use since 
they are ready-to-use packaged products, do not require special preparation, are 
easy to store and act by direct application to the bleeding site [56]. It is important to 
slightly irrigate before removal not to take clotting beneath them. These products 
are relatively inexpensive and well-tolerated, while swelling and increased risk of 
infection are possible side effects [44]. They are usually used as the initial response 
to bleeding [56]. Cellulose-containing products such as Surgicel are commonly used 
since they are cheap and easily accessible. Because these products are absorbable, 
they are easily applied to the bleeding site. They should be used carefully and prac-
tically, as they easily disintegrate by swelling when they get wet or come into con-
tact with blood. Although they can be used directly, we use it by mixing with a small 
amount of cyanoacrylate in a tablespoon for bleedings of difficult to reach points 
such as the posterior of the aortic root during the operation. In this application, the 
most important point to consider is to pay attention to the amount of cyanoacrylate 
used, as it may cause tissue injury. It quickly hardens in a short time when mixed 
with the polymerized cyanoacrylate cellulose. Therefore, it should be applied 
quickly and practically. However, it is not effective in severe bleeding since it does 
not adhere to the tissue. It can be applied hypotensively or by applying compressed 
medical air to the point of bleeding while the blood is removed. Cyanoacrylate 
products prepared for medical purpose can also be used, which should be preferred. 
In emergency situations, products prepared as adhesive can be used as well.
The tablespoon is a simple but effective tool when necessary that should be 
included in the open heart surgery set. It can be very helpful ascending aorta bleed-
ings especially in proximal anastomosis after weaning from CPB, it gives repair 
chance to surgeon by keeping it like a shed 4–5 cm distance above. Also helpful for 
delivering hemostatic powders to bleeding site. It can be herbal powders sold for 
this purpose, as well as crystallized vancomycin powder, which we usually use. It 
can also be helpful in the excision of brittle tissues such as fluid or myxoma.
As a cardiac surgeon, I think the most important side effect of such products 
is that they offer the surgeon extra confidence. The surgeon must provide the 
patient with hemostasis during the operation, otherwise the drainage ongoing in 
the intensive care process brings about serious consequences. For this, the surgeon 
should repeatedly check anastomoses, cardiotomies, surround tissues, especially 
the sternotomy and stop bleeding with appropriate sutures and ligations.
7.2 Active hemostatics
By converting fibrinogen to fibrin, active hemostats—namely the three topical 
thrombin products: bovine thrombin (Thrombin-JMI®), pooled human plasma 
thrombin (Evithrom®), and recombinant thrombin(Recothrom®)—facilitate clot 
formation at the bleeding site [55–57]. Active hemostatic agents are the most com-
monly used adjunctive hemostatic therapies in the surgical setting and conservative 
estimates show that more than one million patients are treated with topical throm-
bin administration annually in the United States [58].
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While all three preparations are applied to the locally bleeding area or larger 
areas in diffuse bleedings in the form of spray, they also require certain preparations 
before application. For example, bovine and recombinant thrombin are stored in 
powder form at room temperature and prepared with certain special liquids before 
use. Pooled human thrombin is available in a liquid form and can be stored in a 
refrigerator for as long as 1 month [56]. In such cases, it should be used together 
with active hemostatic agents such as absorbable gelatin sponge or powder, since 
thrombin administered in the presence of active bleeding can be rapidly irrigated. 
IV should not be used since it may cause a major anaphylactic reaction [59–61].
As the results showed similar efficacy in all three products, health care providers 
canalized their next assessment to select the most appropriate agent for the clinical 
situation. For example, although there are clinical studies showing similar safe use 
of all these products, bovine thrombin administration has been associated with 
antibody formation that can lead to immune-mediated coagulopathy and death, 
which is why this product carries a black box warning [59, 62]. These preparations 
are not available in Turkey. Even if they are, social security providers do not cover 
them since they are very expensive.
7.3 Flowable hemostatic
These products (e.g., Surgiflo®, Floseal®) contain thrombin along with a 
mechanical gelatin agent. They work together to obstruct blood flow and convert 
fibrinogen to fibrin [55, 56]. Although the mechanism of action is similar, Surgiflo 
is porcine gelatin available for use with bovine, human pooled plasma, or recom-
binant thrombin, whereas Floseal includes absorbable bovine gelatin particles 
combined with pooled human thrombin [55, 56]. All these agents are most effective 
in local bleedings and with the help of a syringe, they are applied downward into 
the wound, on the wound edges, providing an ultimate mechanical barrier and 
forming an active clot [55, 56]. The surgeon can spray these agents not only on the 
upper parts of the wound, but also on large irregular surfaces. The product forms a 
thick structure in the bleeding site approximately 3 min after administration. At the 
same time, the surgeon can apply pressure with a sponge soaked with saline [56].
7.4 Fibrin sealant
While many fibrin sealants are available as topical hemostat, sealant and adhe-
sive, Tisseel has received FDA approval for use only [56, 63]. This product is also 
available in our country and is used especially in aortic surgery. Since they contain 
high concentrations of fibrinogen and thrombin, which are naturally found in the 
blood, they cause blood clot formation [56]. Fibrin sealants—namely Tisseel™, 
Evicel®, and Vitagel™—are effective for both local and diffuse bleeding and 
can be applied using either a syringe for local bleeding or spray with a gas-driven 
device for diffuse-bleeding areas [55, 56]. These agents act better when applied to a 
relatively dry surface and can be used with absorbable gelatin sponge as the surgeon 
can press with the finger [56]. In aortic root surgeries such as Bentall procedure, 
after the placement of valved conduit in the aortic root and left coronary button 
anastomosis, Tisseel can be applied to this region providing sealing since this area 
cannot be re-visualized again.
7.5 Albumin and glutaraldehyde
Bovine albumin and glutaraldehyde (BioGlue®) is a cross-linkage between 
bovine serum albumin and 10% glutaraldehyde [56]. It has been approved by the 
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FDA for adhering intimal and adventitial layers to each other in aortic dissection. 
This sealant agent is also available, and we especially use it in aortic surgery dissec-
tions. In particular, it is applied between the layers of the media at the distal of the 
primary intimal tear so the layers are adhered to each other.
7.6 Cyanoacrylates
Octyl cyanoacrylate (e.g., Dermabond™) and butyl cyanoacrylate (e.g., 
Indermil®, Histoacryl®, Histoacryl® Blue) are for topical use only. While these 
agents hold the edges of the skin together, they also form a barrier against bacteria 
[55, 56]. Cyanoacrylates are quick and easy to use, are stored at room temperature, 
and are relatively inexpensive. However, they have an exothermic reaction when 
applied to the skin and thus can cause some discomfort in patients. Safety concerns 
include potential eye injury, and its use on infected, wet, or poorly healing wounds 
should be avoided [55, 56]. N-butyl cyanoacrylate is currently used for endovenous 
ablation of varicose saphenous veins. It is a rapidly polymerizing agent in contact with 
blood. In special cases, it can be applied directly on the tissue and adhered to topical 
hemostatic agents with cellulose content. It is a simple but effective application.
8. Conclusion
What are the limited resources in health care delivery? In underdeveloped and 
developing countries, both the social insurance provider and the delivery of healthcare 
Figure 6. 
Me and my colleague performing a mitral valve operation with classical sternotomy.
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services substantially belong to the state. This has advantages as well as disadvantages. 
These limited resources inevitably create limitations in the delivery of healthcare 
services. If you cannot produce your technology and buy it from outside, these 
products cost too much, and even if they are used, serious limitations are required. 
In this case, the surgical team creates solutions to the current situation; the basic rule 
of being a surgeon is to make the right decision at the right time. At this point, from 
patient admission to surgical planning, the right assessment, the right strategy and the 
right indication should be established for the patient. The surgeon should be skepti-
cal, question and investigate. Beginning a cardiac surgery is an irreversible process. 
Detection and solution of the problems in the preoperative approach will absolutely 
increase the surgical success in the preoperative and postoperative periods.
Right indication and correct surgical planning are absolutely necessary. Your 
nick names have to be patience during surgery. The surgeon’s overconfidence, 
hastiness and misapplication may lead to serious problems. The surgeon and his/
her team should determine all materials required for hemostasis in their hands in 
Figure 7. 
To be a team can figure the problems out in cardiac surgery.
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the preoperative planning and make their preparations accordingly. The blood bank 
is an essential concept in cardiac surgery. It is essential to use blood products by 
determining the patient’s need. Hemostasis should be provided during the opera-
tion and this should not be left to the intensive care process. Creating a solution is 
the basic principle of the surgeon and surgery (Figures 6 and 7).
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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